These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30286103)

  • 41. Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system.
    Magro L; Arzenton E; Moretti U; Sottosanti L; Potenza S; Leone R
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):69-75. PubMed ID: 27875920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dangerous Abuse of a 40-Year-Old Over-the-Counter Medication, Loperamide.
    Shastay A
    Home Healthc Now; 2020; 38(3):167-168. PubMed ID: 32358446
    [No Abstract]   [Full Text] [Related]  

  • 43. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database.
    Durrieu G; Maupiler M; Rousseau V; Chebane L; Montastruc F; Bondon-Guitton E; Montastruc JL
    Paediatr Drugs; 2018 Feb; 20(1):81-87. PubMed ID: 28766184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.
    Bossard JB; Ponté C; Dupouy J; Lapeyre-Mestre M; Jouanjus E
    Clin Drug Investig; 2016 Sep; 36(9):735-742. PubMed ID: 27300651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefit/risk considerations with respect to OTC-descheduling of loperamide.
    Fletcher P; Steffen R; DuPont H
    Arzneimittelforschung; 1995 May; 45(5):608-13. PubMed ID: 7612062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Over-the-counter and prescription medicine misuse in Cape Town--findings from specialist treatment centres.
    Myers B; Siegfried N; Parry CD
    S Afr Med J; 2003 May; 93(5):367-70. PubMed ID: 12830601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Societal perspectives on over-the-counter (OTC) medicines.
    Wazaify M; Shields E; Hughes CM; McElnay JC
    Fam Pract; 2005 Apr; 22(2):170-6. PubMed ID: 15710640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Best Practices and Innovations for Managing Codeine Misuse and Dependence.
    Norman IJ; Bergin M; Parry CD; Van Hout MC
    J Pharm Pharm Sci; 2016; 19(3):367-381. PubMed ID: 27806253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abuse liability of flupirtine revisited: implications of spontaneous reports of adverse drug reactions.
    Gahr M; Freudenmann RW; Connemann BJ; Hiemke C; Schönfeldt-Lecuona C
    J Clin Pharmacol; 2013 Dec; 53(12):1328-33. PubMed ID: 24037995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Torsades de pointes with high-dose loperamide.
    Kozak PM; Harris AE; McPherson JA; Roden DM
    J Electrocardiol; 2017; 50(3):355-357. PubMed ID: 28109524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recreational drug use of over-the-counter (OTC) medication: loperamide and the opiate epidemic.
    Donnelly SC
    QJM; 2020 Jan; 113(1):1. PubMed ID: 31909806
    [No Abstract]   [Full Text] [Related]  

  • 59. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Misuse of OTC drugs in Poland.
    Zaprutko T; Koligat D; Michalak M; Wieczorek M; Józiak M; Ratajczak M; Szydłowska K; Miazek J; Kus K; Nowakowska E
    Health Policy; 2016 Aug; 120(8):875-81. PubMed ID: 27344198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.